SCHEMBL651639

SCHEMBL651639

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC(F)F)cc1)Cc1ccccc1OC(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
TSHR P16473 2/20 0.35
PPARD Q03181 2/20 0.34
PPARA Q07869 1/20 0.34
ALDH1A1 P00352 4/20 0.33
HTT P42858 1/20 0.33
LMNA P02545 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
POLB P06746 1/20 0.33
ATP4A P20648 2/20 0.32
ATP4B P51164 2/20 0.32
DAGLA Q9Y4D2 1/20 0.32
CASR P41180 1/20 0.32
MMP13 P45452 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TLR7 Q9NYK1 1/20 0.31
GAA P10253 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649706 0.95 C5AR1 (0.41) C5AR1TSHRALDH1A1KDM4ECASR
SCHEMBL651033 0.93 C5AR1 (0.44) C5AR1TSHRALDH1A1HTTLMNA
SCHEMBL651956 0.92 C5AR1 (0.43) C5AR1TSHRALDH1A1HTTLMNA
SCHEMBL650574 0.91 C5AR1 (0.41) C5AR1TSHRALDH1A1HTTMAPT
SCHEMBL650580 0.90 C5AR1 (0.41) C5AR1TSHRALDH1A1HTTLMNA
SCHEMBL5135971 0.90 C5AR1 (0.41) C5AR1TSHRALDH1A1HTTLMNA
SCHEMBL652505 0.89 C5AR1 (0.42) C5AR1TSHRALDH1A1HTTLMNA
SCHEMBL648849 0.89 C5AR1 (0.40) C5AR1TSHRPPARDPPARAALDH1A1
SCHEMBL648409 0.89 C5AR1 (0.42) C5AR1TSHRPPARAALDH1A1HTT
SCHEMBL1913032 0.89 C5AR1 (0.41) C5AR1TSHRALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed